Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
NCT02793583 · UNITY-NHL Phase 2/3Terminated
- Lead sponsor
- TG Therapeutics, Inc. (Industry)
- Enrollment
- 710 (actual)
- Start date
- 25 May 2016
- Primary completion
- 31 May 2022 (actual)
- Study completion
- 4 Jul 2022
- Last update posted
- 21 Jul 2022
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 3
Interventions
- Ublituximab Biological
- Umbralisib Drug
- Bendamustine Biological
Conditions and primary outcome
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Small Lymphocytic Lymphoma
Primary outcome
Overall Response Rate (Every 8-12 weeks, up to 2 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedUmbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 May 20
PubMed 33683917 (opens in a new tab)DOI 10.1200/JCO.20.03433 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT02793583 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.